rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

VolitionRX Limited

VNRX · NYSE American

Health CareDiagnostics & LabsNot moving yet

VNRX stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 88.3% below that average now. Diagnostics & Labs: 52% of its 44 stocks in an uptrend (+2 points in four weeks); Health Care: 27% (−6 points in four weeks).

Statistics

Last close, 23 Oct 2026
0.17 +2.96%
52-week range
—
Volume
0.51M
Average volume (50 days)
—
Relative volume
—
Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
52% +2 in 4 wk
Insider buys, 12 months
$7,000
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
26 (-5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

24 Apr – 23 Oct
20%37%53%Apr 26Jun 26Jul 26Sep 26Oct 26

Diagnostics & Labs: About half its stocks are in an uptrend and the share has held steady. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Price and volume

$0.1647$0.2392$0.313711 Sep23 Sep5 Oct14 Oct23 Oct
close

Daily bars to 23 Oct 2026: 30 sessions (1Y reaches back before the first session held here, 11 Sep 2026, so this is all of them). 1D is the last two sessions and 1W the last week of the same daily bars; nothing here is intraday.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$245KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders26-5 on the quarter
New · exited6 · 11
Reported value$2.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Lagoda Investment Management, L.P.reduced · filed 14 Aug 20261,455,950$2.0M-14,693,050−91.0%
LUMINUS MANAGEMENT LLCreduced · filed 14 Aug 2026156,897$212K-838,103−84.2%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202655,537$75K-1,174,546−95.5%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 202650,684$68K-962,989−95.0%
Wealthspire Advisors, LLCreduced · filed 11 Aug 202645,000$61K-175,000−79.5%
STATE STREET CORPreduced · filed 7 Aug 202633,995$46K-645,943−95.0%
XTX Topco Ltdreduced · filed 14 Aug 202625,381$34K-20,679−44.9%
VANGUARD FIDUCIARY TRUST COreduced · filed 13 Aug 202625,133$34K-477,524−95.0%
BlackRock, Inc.reduced · filed 7 Aug 202622,308$30K-423,879−95.0%
NORTHERN TRUST CORPreduced · filed 13 Aug 202612,978$18K-246,615−95.0%
31 Mar 2023 – 30 Jun 2026
212834Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Ann-Louise Batchelor Company insiderGroup Chief Marketing Officer · last 21 Oct 20260 · 0
Gael Forterre Company insiderChief Commercial Officer · last 28 Sep 20260 · 0
Gaetan Michel Company insiderChief Operating Officer · last 28 Sep 20261 · 0
Jacob Vincent Micallef Company insiderChief Scientific Officer · last 17 Mar 20269 · 0
Nicholas Plummer Company insiderGC - Volition Diagnostics · last 17 Mar 20261 · 0
Rodney Gerard Rootsaert Company insiderSecretary · last 17 Mar 20263 · 0
Cameron John Reynolds Company insiderPresident and CEO · last 26 Feb 202616 · 2
Ethel Rubin Company insiderDirector · last 26 Feb 20260 · 0
Guy Archibald Innes Company insiderDirector · last 26 Feb 202622 · 0
Jasmine Kway Company insiderCEO - Singapore Volition · last 26 Feb 20261 · 0
Kim Nguyen Company insiderDirector · last 26 Feb 20261 · 0
Terig Hughes Company insiderChief Financial Officer · last 26 Feb 20260 · 0

Same industry

CDNA CareDxLeading+89%
NTRA NateraLeading+46%
XGN ExagenLeading+36%
PSNL PersonalisLeading+33%
NEOG NeogenLeading+17%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 26 Mar 202626.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$1.1M
Free cash flowFY 2025 · to 31 Dec 2025−$19.8M

Analyst forecasts

No analyst forecasts yet.